{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T13:51:08Z","timestamp":1781877068859,"version":"3.54.5"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T00:00:00Z","timestamp":1769990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T00:00:00Z","timestamp":1769990400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"DOI":"10.1007\/s12094-026-04236-5","type":"journal-article","created":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T11:52:25Z","timestamp":1770033145000},"page":"2665-2674","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Combined positive score status in metastatic triple-negative breast cancer patients treated with sacituzumab govitecan: associated clinical characteristics and testing patterns in a Central European cohort"],"prefix":"10.1007","volume":"28","author":[{"given":"Karolina","family":"Winsko-Szcz\u0119snowicz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ma\u0142gorzata","family":"Pieni\u0105\u017cek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Polakiewicz-Gilowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcin","family":"Kubeczko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milo\u0161","family":"Hol\u00e1nek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miroslava","family":"Malej\u010d\u00edkov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren\u00e1ta","family":"Soumarov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hana","family":"\u0160tudentov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Konieczna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnieszka","family":"M\u0142odzi\u0144ska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justyna","family":"\u017bubrowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maja","family":"Lisik-Habib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anika","family":"P\u0119kala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Krej\u010d\u00ed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"\u0160ustr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iveta","family":"Kol\u00e1\u0159ov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iwona","family":"Danielewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Szymanik-Resko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomasz","family":"Ciszewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lenka","family":"Rusinov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bogumi\u0142a","family":"Czartoryska-Ar\u0142ukowicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"\u0141acko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micha\u0142","family":"Jarz\u0105b","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuzana","family":"Biel\u010dikov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renata","family":"Pacholczak-Madej","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2647-9625","authenticated-orcid":false,"given":"Miros\u0142awa","family":"P\u00fcsk\u00fcll\u00fco\u011flu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,2]]},"reference":[{"key":"4236_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2023.188991","volume":"1878","author":"M P\u00fcsk\u00fcll\u00fco\u011flu","year":"2023","unstructured":"P\u00fcsk\u00fcll\u00fco\u011flu M, Rudzi\u0144ska A, Pacholczak-Madej R. Antibody-drug conjugates in HER-2 negative breast cancers with poor prognosis. Biochimica et Biophysica Acta (BBA) Rev Cancer. 2023;1878:188991. https:\/\/doi.org\/10.1016\/j.bbcan.2023.188991.","journal-title":"Biochimica et Biophysica Acta (BBA) Rev Cancer"},{"key":"4236_CR2","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1056\/NEJMoa2202809","volume":"387","author":"J Cortes","year":"2022","unstructured":"Cortes J, Rugo HS, Cescon DW, Im SA, Yusof MM, Gallardo C, et al. Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer. N Engl J Med. 2022;387:217\u201326. https:\/\/doi.org\/10.1056\/NEJMoa2202809.","journal-title":"N Engl J Med"},{"key":"4236_CR3","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/S1470-2045(20)30754-3","volume":"22","author":"EP Winer","year":"2021","unstructured":"Winer EP, Lipatov O, Im SA, Goncalves A, Mu\u00f1oz-Couselo E, Lee KS, et al. Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22:499\u2013511. https:\/\/doi.org\/10.1016\/S1470-2045(20)30754-3.","journal-title":"Lancet Oncol"},{"key":"4236_CR4","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1016\/S0140-6736(20)32531-9","volume":"396","author":"J Cortes","year":"2020","unstructured":"Cortes J, Cescon DW, Rugo HS, Nowecki Z, Im SA, Yusof MM, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355). Lancet. 2020;396:1817\u201328. https:\/\/doi.org\/10.1016\/S0140-6736(20)32531-9.","journal-title":"Lancet"},{"key":"4236_CR5","unstructured":"NCCN Clinical Practice Guidelines in Oncology. Breast Cancer. Version 4.2025. NCCN; 2025. Accessed 17 April 2025."},{"key":"4236_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2024.103756","volume":"76","author":"F Cardoso","year":"2024","unstructured":"Cardoso F, Paluch-Shimon S, Schumacher-Wulf E, Matos L, Gelmon K, Aapro MS, et al. 6th and 7th international consensus guidelines for the management of advanced breast cancer (ABC guidelines 6 and 7). Breast. 2024;76:103756. https:\/\/doi.org\/10.1016\/j.breast.2024.103756.","journal-title":"Breast"},{"issue":"Suppl","key":"4236_CR7","doi-asserted-by":"publisher","first-page":"LBA109","DOI":"10.1200\/JCO.2025.43.17_suppl.LBA109","volume":"43","author":"SM Tolaney","year":"2025","unstructured":"Tolaney SM, de Azambuja E, Kalinsky K, Loi S, Kim SB, Yam C, et al. Sacituzumab govitecan plus pembrolizumab vs chemotherapy plus pembrolizumab in untreated PD-L1\u2013positive advanced triple-negative breast cancer: primary results from ASCENT-04\/KEYNOTE-D19. J Clin Oncol. 2025;43(Suppl):LBA109. https:\/\/doi.org\/10.1200\/JCO.2025.43.17_suppl.LBA109.","journal-title":"J Clin Oncol"},{"key":"4236_CR8","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1056\/NEJMoa1910549","volume":"382","author":"P Schmid","year":"2020","unstructured":"Schmid P, Cortes J, Pusztai L, McArthur H, K\u00fcmmel S, Bergh J, et al. Pembrolizumab for early triple-negative breast cancer. N Engl J Med. 2020;382:810\u201321. https:\/\/doi.org\/10.1056\/NEJMoa1910549.","journal-title":"N Engl J Med"},{"key":"4236_CR9","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1093\/jnci\/djab121","volume":"114","author":"SS Badve","year":"2021","unstructured":"Badve SS, Penault-Llorca F, Reis-Filho JS, Deurloo R, Siziopikou KP, D\u2019Arrigo C, et al. Determining PD-L1 status in patients with triple-negative breast cancer: lessons learned from IMpassion130. J Natl Cancer Inst. 2021;114:664\u201372. https:\/\/doi.org\/10.1093\/jnci\/djab121.","journal-title":"J Natl Cancer Inst"},{"key":"4236_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2023.104103","volume":"190","author":"N Fusco","year":"2023","unstructured":"Fusco N, Ivanova M, Frascarelli C, Criscitiello C, Cerbelli B, Pignataro MG, et al. Advancing the PD-L1 CPS test in metastatic TNBC: insights from pathologists and findings from a nationwide survey. Crit Rev Oncol Hematol. 2023;190:104103. https:\/\/doi.org\/10.1016\/j.critrevonc.2023.104103.","journal-title":"Crit Rev Oncol Hematol"},{"key":"4236_CR11","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.humpath.2024.01.008","volume":"144","author":"M Ivanova","year":"2024","unstructured":"Ivanova M, Frascarelli C, Cerbelli B, Pignataro MG, Pernazza A, Venetis K, et al. PD-L1 testing in metastatic triple-negative breast cancer: interobserver and interplatform reproducibility of CE-IVD assays for CPS and IC scores. Hum Pathol. 2024;144:22\u20137. https:\/\/doi.org\/10.1016\/j.humpath.2024.01.008.","journal-title":"Hum Pathol"},{"key":"4236_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-023-01724-2","volume":"25","author":"G Sigurjonsdottir","year":"2023","unstructured":"Sigurjonsdottir G, De Marchi T, Ehinger A, Hartman J, Bosch A, Staaf J, et al. Comparison of SP142 and 22C3 PD-L1 assays in a population-based cohort of triple-negative breast cancer patients in the context of their clinically established scoring algorithms. Breast Cancer Res. 2023;25:117. https:\/\/doi.org\/10.1186\/s13058-023-01724-2.","journal-title":"Breast Cancer Res"},{"key":"4236_CR13","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1093\/oncolo\/oyad025","volume":"28","author":"N Danziger","year":"2023","unstructured":"Danziger N, Sokol ES, Graf RP, Hiemenz MC, Maule J, Parimi V, et al. Variable landscape of PD-L1 expression in breast carcinoma as detected by the DAKO 22C3 immunohistochemistry assay. Oncologist. 2023;28:319\u201326. https:\/\/doi.org\/10.1093\/oncolo\/oyad025.","journal-title":"Oncologist"},{"key":"4236_CR14","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.humpath.2020.11.004","volume":"108","author":"X Huang","year":"2021","unstructured":"Huang X, Ding Q, Guo H, Gong Y, Zhao J, Zhao M, et al. Comparison of three FDA-approved diagnostic immunohistochemistry assays of PD-L1 in triple-negative breast carcinoma. Hum Pathol. 2021;108:42\u201350. https:\/\/doi.org\/10.1016\/j.humpath.2020.11.004.","journal-title":"Hum Pathol"},{"key":"4236_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13058-023-01710-8","volume":"25","author":"JE Choi","year":"2023","unstructured":"Choi JE, Lee JS, Jin MS, Nikas IP, Kim K, Yang S, et al. The prognostic value of a combined immune score in tumor and immune cells assessed by immunohistochemistry in triple-negative breast cancer. Breast Cancer Res. 2023;25:1\u201317. https:\/\/doi.org\/10.1186\/s13058-023-01710-8.","journal-title":"Breast Cancer Res"},{"key":"4236_CR16","doi-asserted-by":"publisher","unstructured":"Medi\u0107-Miliji\u0107 N, Jovani\u0107 I, Nedeljkovi\u0107 M, Markovi\u0107 I, Spurni\u0107 I, Milovanovi\u0107 Z, et al. Prognostic and clinical significance of PD-L1, EGFR and androgen receptor (AR) expression in triple-negative breast cancer (TNBC) patients. Life. 2024;14:682. https:\/\/doi.org\/10.3390\/life14060682.","DOI":"10.3390\/life14060682"},{"key":"4236_CR17","doi-asserted-by":"publisher","unstructured":"Guo Y, Yu P, Liu Z, Maimaiti Y, Wang S, Yin X, Liu C, Huang T. Prognostic and clinicopathological value of programmed death ligand-1 in breast cancer: a meta-analysis. PLoS One. 2016;11(5):e0156323. https:\/\/doi.org\/10.1371\/journal.pone.0156323.","DOI":"10.1371\/journal.pone.0156323"},{"key":"4236_CR18","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1016\/j.annonc.2021.09.019","volume":"32","author":"A Gennari","year":"2021","unstructured":"Gennari A, Andr\u00e9 F, Barrios CH, Cort\u00e9s J, de Azambuja E, DeMichele A, et al. ESMO clinical practice guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Ann Oncol. 2021;32:1475\u201395. https:\/\/doi.org\/10.1016\/j.annonc.2021.09.019.","journal-title":"Ann Oncol"},{"key":"4236_CR19","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13236090","volume":"13","author":"MB Cirqueira","year":"2021","unstructured":"Cirqueira MB, Mendon\u00e7a CR, Noll M, Soares LR, de Paula Carneiro Cysneiros MA, Paulinelli RR, et al. Prognostic role of PD-L1 expression in invasive breast cancer: a systematic review and meta-analysis. Cancers. 2021;13:6090. https:\/\/doi.org\/10.3390\/cancers13236090.","journal-title":"Cancers"},{"key":"4236_CR20","doi-asserted-by":"publisher","first-page":"31347","DOI":"10.18632\/oncotarget.15532","volume":"8","author":"M Zhang","year":"2017","unstructured":"Zhang M, Sun H, Zhao S, Wang Y, Pu H, Zhang Q. Expression of PD-L1 and prognosis in breast cancer. Oncotarget. 2017;8:31347\u201358. https:\/\/doi.org\/10.18632\/oncotarget.15532.","journal-title":"Oncotarget"},{"key":"4236_CR21","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000015201","volume":"98","author":"S Li","year":"2019","unstructured":"Li S, Chen L, Jiang J. Role of programmed cell death ligand-1 expression on prognostic and overall survival of breast cancer: A systematic review and meta-analysis. Medicine. 2019;98:e15201. https:\/\/doi.org\/10.1097\/MD.0000000000015201.","journal-title":"Medicine"},{"key":"4236_CR22","doi-asserted-by":"publisher","first-page":"33972","DOI":"10.18632\/oncotarget.5583","volume":"6","author":"T Qin","year":"2015","unstructured":"Qin T, Zeng YD, Qin G, Xu F, Lu JB, Fang WF, et al. High PD-L1 expression was associated with poor prognosis in 870 Chinese patients with breast cancer. Oncotarget. 2015;6:33972\u201381. https:\/\/doi.org\/10.18632\/oncotarget.5583.","journal-title":"Oncotarget"},{"key":"4236_CR23","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/s10555-022-10060-4","volume":"41","author":"MZ Wojtukiewicz","year":"2022","unstructured":"Wojtukiewicz MZ, Pogorzelska M, Politynska B. Immunotherapy for triple-negative breast cancer: the end of the beginning or the beginning of the end? Cancer Metastasis Rev. 2022;41:465\u201382. https:\/\/doi.org\/10.1007\/s10555-022-10060-4.","journal-title":"Cancer Metastasis Rev"},{"key":"4236_CR24","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1080\/13543784.2022.2049232","volume":"31","author":"E Agostinetto","year":"2022","unstructured":"Agostinetto E, Losurdo A, Nader-Marta G, Santoro A, Punie K, Barroso R, et al. Progress and pitfalls in the use of immunotherapy for patients with triple-negative breast cancer. Expert Opin Investig Drugs. 2022;31:567\u201391. https:\/\/doi.org\/10.1080\/13543784.2022.2049232.","journal-title":"Expert Opin Investig Drugs"},{"key":"4236_CR25","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1007\/s11864-023-01069-0","volume":"24","author":"V Geurts","year":"2023","unstructured":"Geurts V, Kok M. Immunotherapy for metastatic triple negative breast cancer: current paradigm and future approaches. Curr Treat Options Oncol. 2023;24:628\u201343. https:\/\/doi.org\/10.1007\/s11864-023-01069-0.","journal-title":"Curr Treat Options Oncol"},{"key":"4236_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2022.903065","volume":"9","author":"R Ribeiro","year":"2022","unstructured":"Ribeiro R, Carvalho MJ, Goncalves J, Moreira JN. Immunotherapy in triple-negative breast cancer: insights into tumor immune landscape and therapeutic opportunities. Front Mol Biosci. 2022;9:903065. https:\/\/doi.org\/10.3389\/fmolb.2022.903065.","journal-title":"Front Mol Biosci"},{"key":"4236_CR27","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1038\/s41379-020-0606-0","volume":"33","author":"RS Hoda","year":"2020","unstructured":"Hoda RS, Brogi E, Dos Anjos CH, Grabenstetter A, Ventura K, Patil S, et al. Clinical and pathologic features associated with PD-L1 (SP142) expression in stromal tumor-infiltrating immune cells of triple-negative breast carcinoma. Mod Pathol. 2020;33:2221\u201332. https:\/\/doi.org\/10.1038\/s41379-020-0606-0.","journal-title":"Mod Pathol"},{"key":"4236_CR28","doi-asserted-by":"publisher","first-page":"349","DOI":"10.2147\/BCTT.S499373","volume":"17","author":"ALS Dos Santos","year":"2025","unstructured":"Dos Santos ALS, Da Silva JL, De Albuquerque LZ, Neto ALA, Da Silva CF, Cerva LAM, et al. Unveiling the landscape of PD-L1 expression and tumor-infiltrating lymphocyte subtypes in advanced triple-negative breast cancer in Brazil. Breast Cancer Targets Ther. 2025;17:349\u201358. https:\/\/doi.org\/10.2147\/BCTT.S499373.","journal-title":"Breast Cancer Targets Ther"},{"key":"4236_CR29","doi-asserted-by":"publisher","first-page":"301","DOI":"10.5114\/pjp.2020.103710","volume":"71","author":"\u0141 Szylberg","year":"2021","unstructured":"Szylberg \u0141, Antoniewicz E, Olszewski W, Kowalewski A, Zdrenka M, Dziekan B, et al. PD-L1 expression in triple-negative breast cancer: a cross-sectional study in a Polish population. Pol J Pathol. 2021;71:301\u20136. https:\/\/doi.org\/10.5114\/pjp.2020.103710.","journal-title":"Pol J Pathol"},{"key":"4236_CR30","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.breast.2021.11.003","volume":"60","author":"A Noske","year":"2021","unstructured":"Noske A, Wagner DC, Schwamborn K, Foersch S, Steiger K, Kiechle M, et al. Interassay and interobserver comparability study of four programmed death-ligand 1 (PD-L1) immunohistochemistry assays in triple-negative breast cancer. Breast. 2021;60:238\u201344. https:\/\/doi.org\/10.1016\/j.breast.2021.11.003.","journal-title":"Breast"},{"key":"4236_CR31","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.mpdHP.2023.12.001","volume":"30","author":"A Baltan","year":"2024","unstructured":"Baltan A, Costache S, Shaaban AM, D\u2019Arrigo C. Review of immune checkpoint blockade and PD-L1 testing in breast cancer. Diagn Histopathol. 2024;30:110\u201322. https:\/\/doi.org\/10.1016\/j.mpdHP.2023.12.001.","journal-title":"Diagn Histopathol"},{"key":"4236_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2021.102257","volume":"99","author":"C Boman","year":"2021","unstructured":"Boman C, Zerdes I, M\u00e5rtensson K, Bergh J, Foukakis T, Valachis A, et al. Discordance of PD-L1 status between primary and metastatic breast cancer: a systematic review and meta-analysis. Cancer Treat Rev. 2021;99:102257. https:\/\/doi.org\/10.1016\/j.ctrv.2021.102257.","journal-title":"Cancer Treat Rev"},{"key":"4236_CR33","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1093\/annonc\/mdy399","volume":"29","author":"B Szekely","year":"2018","unstructured":"Szekely B, Bossuyt V, Li X, Wali VB, Patwardhan GA, Frederick C, et al. Immunological differences between primary and metastatic breast cancer. Ann Oncol. 2018;29:2232\u20139. https:\/\/doi.org\/10.1093\/annonc\/mdy399.","journal-title":"Ann Oncol"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04236-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-026-04236-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04236-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T12:58:06Z","timestamp":1781873886000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-026-04236-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,2]]},"references-count":33,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["4236"],"URL":"https:\/\/doi.org\/10.1007\/s12094-026-04236-5","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,2]]},"assertion":[{"value":"17 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Karolina Winsko-Szcz\u0119snowicz received travel support and lecture honoraria from Roche, Eli Lilly, Novartis, Pfizer, Gilead, MSD, and Aurovitas. Ma\u0142gorzata Pieni\u0105\u017cek received travel support and lecture fees from Pfizer and Novartis; lecture fees from Gilead; and participated in an advisory board for Novartis. Anna Polakiewicz-Gilowska received lecture honoraria and travel support from AstraZeneca, Roche, Novartis, Eli Lilly, Swixx Biopharma, Gilead, and Pfizer. Marcin Kubeczko served on advisory boards for Novartis; received speaker\u2019s fees and conference support from Novartis, Roche, MSD, Pfizer, Eli Lilly, Teva, Amgen, Swixx Biopharma, AstraZeneca, and Gilead; and participated in clinical trials sponsored by Roche, MSD, Novartis, Seagen, and Gilead. Milo\u0161 Hol\u00e1nek received travel and conference support from MSD, Gilead, Eli Lilly, and AstraZeneca; received lecture and speaker\u2019s fees from Novartis, Gilead, Eli Lilly, and Teva; and served on advisory boards for AstraZeneca, Eli Lilly, and Gilead. Miroslava Malej\u010d\u00edkov\u00e1 served as a consultant and expert advisor for Novartis, Amgen, Pfizer, Roche, and AstraZeneca; received honoraria from Novartis, Pfizer, Roche, Teva, and AstraZeneca; and participated in clinical studies sponsored by Novartis, Roche, AstraZeneca, and Pfizer. Ren\u00e1ta Soumarov\u00e1 received honoraria and support from BMS, AstraZeneca, Pfizer, Novartis, Eli Lilly, MSD, Gilead, Janssen, Astellas, Servier, Accord, and GSK, including advisory board participation. Hana \u0160tudentov\u00e1 received speaker\u2019s fees and conference support from Novartis, MSD, Janssen, Astellas, Pfizer, Richter Gedeon, AstraZeneca, and Ipsen. Aleksandra Konieczna received travel grants and lecture fees from Pfizer, Novartis, Eli Lilly, MSD, AstraZeneca, and Gilead; and advisory board honoraria from Novartis. Agnieszka M\u0142odzi\u0144ska received lecture honoraria from Novartis, Swixx Biopharma, and Gilead; received travel support from Eli Lilly, Pfizer, and Novartis. Justyna \u017bubrowska received travel grants and lecture fees from MSD, Novartis, and AstraZeneca; and lecture fees from Pfizer, Swixx Biopharma, and Eli Lilly. Maja Lisik-Habib received honoraria for lectures from MSD, AstraZeneca, Johnson & Johnson, Roche, BMS, Astellas, Merck, and GSK. Anika P\u0119kala declares no conflicts of interest. Daniel Krej\u010d\u00ed received honoraria, congress fees, and travel support from MSD, AstraZeneca, Novartis, Eli Lilly, Roche, and Pfizer. Jan \u0160ustr received conference support from Gilead and MSD; and speaker\u2019s fees from AstraZeneca and MSD. Iveta Kol\u00e1\u0159ov\u00e1 received honoraria and support from AstraZeneca, Novartis, MSD, Eli Lilly, Roche, Swixx Biopharma, and Gilead, including advisory board participation. Iwona Danielewicz declares no conflicts of interest. Magdalena Szymanik-Resko declares no conflicts of interest. Tomasz Ciszewski received travel grants and lecture fees from Pfizer, Novartis, Eli Lilly, MSD, Roche, Gilead, and AstraZeneca. Lenka Rusinov\u00e1 declares no conflicts of interest. Bogumi\u0142a Czartoryska-Ar\u0142ukowicz received travel grants and lecture fees from Eli Lilly, Novartis, Pfizer, AstraZeneca, Gilead, and Roche. Aleksandra \u0141acko received honoraria and support from AstraZeneca, Pfizer, Novartis, Eli Lilly, Roche, and Gilead Sciences, including advisory board participation. Micha\u0142 Jarz\u0105b received conference support from Gilead and Roche; speaker\u2019s fees from Novartis, Roche, Eli Lilly, Pfizer, Teva, Exact Sciences, and Mammotome; and served on advisory boards for Novartis and Pfizer. Zuzana Biel\u010dikov\u00e1 received travel grants and lecture honoraria from AstraZeneca, MSD, Roche, Novartis, Eli Lilly, and Gilead. Renata Pacholczak-Madej received travel grants from Accord and BMS; and lecture fees from AstraZeneca, BMS, MSD, GSK, Novartis, and Roche. Miros\u0142awa P\u00fcsk\u00fcll\u00fco\u011flu received travel grants and lecture honoraria from AstraZeneca, Roche, Novartis, Eli Lilly, Janssen, Gilead, and Amgen.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"This study received ethical clearance from the institutional review boards of the Maria Sklodowska-Curie National Research Institute of Oncology in Krakow (approval no. 2\/2023, dated 18 April 2023) and Warsaw (approval no. 21\/2024, dated 22 February 2024) and ethical clearance from the institutional review boards of the Masaryk Memorial Cancer Institute in Brno (approval no 1737\/2025, dated 10 June 2025) and approval of the Ethics Committee of the General University Hospital in Prague (approval no 110825 S-IV dated 21 August 2025). All human-related research activities were conducted in accordance with institutional standards and the ethical guidelines set forth in the Declaration of Helsinki (1964) and its subsequent revisions.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The ethics committees determined that separate consent for retrospective analysis of clinical data was not necessary.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}